KEYTRUDA Ovarian Cancer Treatments: FDA Approve...

By João L. Carapinha

February 11, 2026

KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and be...
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Surge in Obesity Intervention Costs in the Netherlands
HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Characterizing Burnout in Health Professionals: Insights from the BEATS Study...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment